A new study finds that combining the current medications for Alzheimer’s disease with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric is a safer and more effective way to treat the disease.

Individuals with Alzheimer’s have a buildup of toxic amyloid proteins in the brain. Researchers from the School of Pharmacy at the University of Waterloo combined amyloid-destroying small molecules with anti-amyloid antibodies that are already used in Alzheimer’s treatment.

Scientists at the Buck Institute for Research on Aging have shown that an orally administered small molecule, N-propargylglycine (N-PPG), can completely prevent the formation of calcium oxalate kidney stones, protect against kidney failure, and fully restore normal survival in a mouse model of Primary Hyperoxaluria Type 2 (PH2), a rare and currently untreatable genetic disorder that causes progressive kidney failure in infants and young adults.

Fans of Korean skincare may be familiar with ‘hero ingredient’ Madecassic acid for its skin-soothing properties, but researchers at the University of Kent have revealed its greater potential for use in the battle against antibiotic resistance.

Using a combination of computational screening and laboratory experiments, scientists in the School of Natural Sciences together with those at University College London (UCL) have demonstrated how this natural chemical from the common Asian herb Centella asiatica, is an effective antibacterial drug.

University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines.

UVA’s Nikolay V. Dokholyan, PhD, and colleagues have developed a suite of artificial intelligence-powered tools, called YuelDesign, YuelPocket and YuelBond, that work together to transform how new drugs are created.

Scripps Research scientists have developed a new class of drug compounds that reduce harmful inflammation while leaving the body’s ability to fight infections intact - a long-sought goal in treating autoimmune diseases. The compounds, called ENDOtollins, work by interrupting a “molecular handshake” between two proteins inside immune cells.

In a paper published in the Journal of Clinical Investigation, a research team at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health reports developing a therapeutic intranasal (nose-delivered) DNA vaccine against tuberculosis (TB) that fuses two genes with the goal of directing the immune system to fight drug-tolerant bacterial “persisters” that can survive prolonged antibiotic therapy and contribute to disease relapse.

A hormone that reverses obesity in mice appears to work by signaling to a brain region involved in metabolism and appetite regulation, the same area targeted by the popular GLP-1 drugs. The finding, from University of Oklahoma researchers, is published in Cell Reports.

The study provides valuable new insight into the naturally occurring hormone, called FGF21 (fibroblast growth factor 21), which is already involved in drug development.